Further accelerating biologics development from DNA to IND: the journey from COVID-19 to non-COVID-19 programs
Description
                The Coronavirus Disease (COVID-19) pandemic has spurred adoption of revolutionary initiatives by regulatory agencies and pharmaceutical industry worldwide to deliver therapeutic COVID-19 antibodies to patients at unprecedented speed. Among these
          